Abstract
Elevated levels of reactive oxygen species (ROS) and accumulation of misfolded α-synuclein (αSYN) are recurrent features in a majority of Parkinson’s disease cases. Building on the brain energy metabolism framework in Chap. 2, a mathematical model is constructed of these key neurochemical players and their interactions. A computer implementation of the model is used to simulate and visualize the dynamics of ROS, αSYN, and their nonlinear interaction within a positive feedback loop. The most important observation from this modeling is that the homogenous nature of known biomarkers (ROS/αSYN) can be reconciled with the heterogeneous nature of the underlying risk factors, including aging, genetics, and toxins. More specifically, our model uses risk factors (aging, toxins) as “inputs” and then provides estimates of PD susceptibility based on their propensity to destabilize the model system. The stability of the model is then used as a criterion to quantify the level of various risks. The importance of rapid biochemical dynamics in evaluating the impact of neuroprotective strategies is also highlighted, with simulations demonstrating the synergistic effect of creatine and antioxidants in buffering ROS levels during transient conditions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lotharius J, Brundin P (2002) Pathogenesis of Parkinson’s Disease. Nat Rev Neurosci 3:932
Malkus KA, Tsika E, Ischiropoulos H (2009) Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson’s disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener 4:24
Litvan I, Halliday G (2007) The etiopathogenesis of Parkinson’s disease and suggestions for future research. J Neuropathol Exp Neurol 1 66:251–257
Powers WJ (2008) Cerebral mitochondrial metabolism in early Parkinson’s disease. J Cereb Blood Flow Metab 28:1754
Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36
Gibb WR, Lees AJ (1998) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752
Cookson MR (2009) Alpha-Synuclein and neuronal cell death. Mol Neurodegener 4:9
Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283(14):9089–9100
Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA (2006) Parkinson’s disease alpha-synuclein transgenic mice develops neuronal mitochondrial degeneration and cell death. J Neurosci 26:41–50
Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF (2006) Mice lackin alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21:541–548
Braak H, Ghembremedhin E, Rb U, Bratzke H, Tredici K (2004) Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 318(1):121–134
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Bennett MC, Bishop JF, Leng Y, Chock PB, Chase TN, Mouradian MM (1999) Degradation of alpha-synuclein by proteasome. J Biol Chem 274:33855–33858
Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, and oxidative stress. J Biol Chem 272(33):20313–20316. doi:10.1074/jbc.272.33.20313
Lodish H, Berk A, Kaiser CK, Krieger M, Scott MP, Bretscher A, Ploegh H, Matsudeira P (2000) Molecular cell biology, 6th edn. W.H. Freeman and Company, New York, NY
Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D (2009) Interplay between cytosolic dopamine, calcium and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 62:218–229
Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT (2002) Amyloid pores from pathogenic mutations. Nat Rev Neurosci 418:291
van Rooijen BD, Claessens MMAE, Subramaniam V (2009) Lipid bilayer disruption by oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic core. Biochim Biophys Acta 1788:1271–1278
Frase H, Hudak J, Lee I (2006) Identification of the proteasome inhibitor MG262 as a potent ATP-dependent inhibitor of the Salmonella enterica serovar Typhimurium Lon Proteaseâ. Biochemistry 45(27):8264–8274. doi:10.1021/bi060542e
Cortes VF, Veiga-Lopes FE, Barrabin H, Alves-Ferreira M, Fontes CFL (2006) The [gamma] subunit of Na+, K+-ATPase: role on ATPase activity and regulatory phosphorylation by PKA. Int J Biochem Cell Biol 38(11):1901–1913
Cloutier M, Bolger FB, Lowry JP, Wellstead P (2009) An integrative dynamic model of brain energy metabolism using in vivo neurochemical measurements. J Comput Neurosci 27:391–414
Cloutier M, Wellstead P (2010) The control systems structures of energy metabolism. J R Soc Interface 7:651–665
Wellstead P, Cloutier M (2011) An energy systems approach to Parkinson’s disease. WIREs Syst Biol Med 3:1–6
Cloutier M, Wellstead P (2011) Dynamic modelling of protein and oxidative metabolisms simulates the pathogenesis of Parkinson’s disease. IET Syst Biol (In press). doi:10.1049/iet-syb.2011.0071
Cloutier M, Middleton RH, Wellstead P (2011) A feedback motif for the pathogenesis of Parkinson’s disease. IET Syst Biol (In press). doi:10.1049/iet-syb.2011.0072
Stanley F (1996) The case of the frozen addicts. N Engl J Med 335:2002
Schmidt H, Jirstrand M (2006) Systems biology toolbox for Matlab: a computational platform for research in systems biology. Bioinformatics 22(4):514–515
Underwood AH, Holmes EA (1965) Properties of phosphofructokinase from rat liver and their relation to the control of glycolysis and gluconeogenesis. Biochem J 95:868–875
Heinrich R, Schuster S (1996) The regulation of cellular systems. ITP Chapman & Hall, New York, NY
Heldt HW, Klingenberg M, Milovancev M (1972) Differences between the ATP/ADP ratios in the mitochondrial matrix and in the extramitochondrial space. Eur J Biochem 30:434–440
Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci 91:10625–10629
Proctor CJ, Csaba S, Boys RJ, Gillespie CS, Shanley DP, Wilkinson DJ, Kirkwood BL (2005) Modelling the actions of chaperones and their role in ageing. Mech Ageing Dev 126:119–131
Fai Poon H, Frasier M, Shreve N, Calabrese V, Wolozin B, Butterfield DA (2005) Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice—a model of familial Parkinson’s disease. Neurobiol Dis 18:492–498
Shlomi T, Benyamini T, Gottlieb E, Sharan R, Ruppin E (2011) Genome-scale metabolic modeling elucidates the role of proliferative adaptation in causing the Warburg effect. PLoS Comput Biol 7(3):e1002018
Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, Patel N, Yee A, Lewis RA, Eils R, Konig R, Palsson BO (2010) Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol 28(12):1279–1285
Magistretti P (2006) Neuron-glia metabolic coupling and plasticity. J Exp Biol 209:2304–2311
Clark DD, Sokoloff L (1999) Circulation and energy metabolism. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD (eds) Basic neurochemistry: molecular, cellular, and medical aspects, 6th edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 638–669
Proctor CJ, Tsirigotis M, Gray DA (2007) An in silico model of the ubiquitin-proteasome system that incorporates normal homeostasis and age-related decline. BMC Syst Biol 1:17
Sneppen K, Lizana L, Jensen MH, Pigolotti S, Otzen D (2009) Modelling proteasome dynamics in Parkinson’s disease. Phys Biol 6:036005
Raichur A, Vali S, Gorin F (2006) Dynamic modeling of alpha-synuclein aggregation for the sporadic and genetic forms of Parkinson’s disease. Neuroscience 142:859–870
Bharathi P, Nagabhushan P, Rao KSJ (2008) Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson’s disease. Comput Biol Med 38:1084–1093
Lei B, Adachi N, Arai T (1998) Measurement of the extracellular H2O2 in the brain by microdialysis. Brain Res Protocols 3:33–36
Desagher S, Glowinski J, Premont J (1996) Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 16:2553–2562
Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Mardsen CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–829
Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E (2004) Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 186:158–172
Tyson JJ, Chen KC, Novak B (2003) Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signalling pathways in the cell. Curr Opin Cell Biol 15:221–231
Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2009) MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F and Myc. Proc Natl Acad Sci 105:19678–19683
Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Flint Beal M (2009) Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. J Neurochem 109(5):1427–1439. doi:10.1111/j.1471-4159.2009.06074.x
Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM, for the NETPDI (2009) Determinants of the timing of symptomatic treatment in early Parkinson disease: the national institutes of health exploratory trials in parkinson disease (NET-PD) experience. Arch Neurol 66(9):1099–1104. doi:10.1001/archneurol.2009.159
Ben-Yoseph O, Camp DM, Robinson TE, Ross BD (1995) Dynamic measurements of cerebral pentose phosphate pathway activity in vivo using [1,6-13 C2,6,6-2 H2] glucose and microdialysis. J Neurochem 64(3):1336–1342
Vali S, Mythri RB, Jagatha B, Padiapu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MMS (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson’s disease: a dynamic model. Neuroscience 149:917–930
Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21(10):1133–1145
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Cloutier, M., Wellstead, P. (2012). Modeling Protein and Oxidative Metabolism in Parkinson’s Disease. In: Wellstead, P., Cloutier, M. (eds) Systems Biology of Parkinson's Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3411-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3411-5_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3410-8
Online ISBN: 978-1-4614-3411-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)